RESEARCH PAPER
In vivo investigations of neurotensin receptors in adipocytes, hepatocytes and enterocytes of rat
 
More details
Hide details
1
Department of Physiology and Biochemistry, University of Life Sciences, Poznań, Poland
2
Department of Physiology, University of Medical Sciences, Poznań, Poland; Institute of Rural Health, Lublin, Poland
3
Department of Physiology, University of Medical Sciences, Poznań, Poland
4
Department of Internal Medicine, Metabolic Disorders and Hypertension, University of Medical Sciences, Poznań, Poland
 
Ann Agric Environ Med. 2011;18(2):433–436
KEYWORDS
ABSTRACT
Introduction: Atherosclerotic vascular disease is currently the biggest threat and the highest cause of death worldwide, approaching almost 60%.The development of atherosclerosis is affected by ecological factors associated with industry and pollution of the environment. Neurotensin (NT) is a peptide acting via 3 kinds of neurotensin receptors (NTR) localized in target tissues. In several studies, the presence of its receptors has been shown in chicken liver, and the influence of NT on the metabolism of this organ was confirmed (glycogenolysis stimulation through sympathetic nervous system, entero-hepatic circulation of bile acids, metabolism of lipoproteins). Materials and methods: Healthy male WISTAR rats weighing 300±30 grams, were used for the experiments. The animals were divided into 4 groups: 1) control group, to which 0.9% NaCl was administrated (i.p.); 2) the second group was given levocabastine 1mg/kg i.p.; 3) the third group received SR 48692 0.4mg/; 4) the fourth group was given NT analog [D-Trp 11]-neurotensin 15nM/kg. Plasmatic membranes of liver, small intestine and adipose tissue were prepared according to the method of Havrankova. Analysis of results obtained in the investigation of NT receptors was performed using the Scatchard method from LIGAND-Pc, v. 3.1 software. Results: The investigation of antigenity of I 125 NT showed proper antigen-antibody reaction. No binding of the I 125 NT with plasmatic membranes of adipocytes or enterocytes was observed. Unspecifi c binding of I 125 NT with 10 μmol/L of free NT was observed in the plasmatic membranes of hepatocytes. Conclusion: The presence of NT receptors only in the membranes of hepatocytes may suggest their role in the regulation of lipid metabolism via receptor – ligand way.
 
REFERENCES (28)
1.
Piątek J, Witmanowski H, Paluszak J, Krauss H, Krawczyk J.Th e eff ects of neurotensin on selected parameters of lipid metabolism in rats. Peptides 2005 (in press).
 
2.
Carraway RE: Neurotensin. In: Becker K (Ed.). Principles and practice of endocrinology and metabolism, JB.Lippincott, Philadelphia (PA) 1989;1:1303-1307.
 
3.
Maoret JJ, Anini Y, Rouyer-Fessard C, Gully D, Laburthe M. Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenograft ed into nude mice. Int J Cancer 1999;80(3):448-54.
 
4.
Carraway RE, Ferris CF. Isolation, biological and chemical characterization and the synthesis of neurotensin-related hexapeptide from chicken intestine. J Biol Chem1983;258:2475-2479.
 
5.
Carraway RE, Leeman SE. Characterization of radioimmunoassayable neurotensin in the rat. J Biol Chem1976;251:7035-7044.
 
6.
Ferris CF, Armstrong MJ, George JK, Stevens CA, Carraway RE, Leeman SE. Alcohol and fatty acid stimulation of neurotensin release from rat small intestine. Endocrinology 1985;116:1133-1138.
 
7.
Munson PJ, Rodbard D. LIGAND: A versatile computerized approach for characterization of ligand-binding systems. Analytic Biochem 1980;107:220-239.
 
8.
Goedert M, Pinnock RD, Downes CP, Mantyh PW, Emson PC. Neurotensin stimulates inositol phospholipids hydrolysis in rat brain slices. Brain Res 1984;323:193-197.
 
9.
Shi WX, Bunney BS. Roles of intracellular cAMP and protein kinase A in the actions of dopamine neurons. J Neurosci 1992;12:2433-2438.
 
10.
McMahon BM, Mays D, Lipsky J, Stewart JA, Fauq A, Richelson E. Pharmacokinetics and tissue distribution of a peptide nucleic acid aft er intravenous administration. Antisense Nucleic Acid Drug Dev 2002;12(2):65-70.
 
11.
Havrankova J, Schmechel D, Roth J, Brownstein M. Identifi cation of insulin in rat brain. Proc Natl Acad Sci (USA) 1978;75(11):5737-5741.
 
12.
Kokko KP, Hadden MK, Orwig K, Mazella J, Dix TA. In vitro analysis of stable, receptor-selective neurotensin [8-13] analogues. J Med Chem 2003;46(19):4141-4148.
 
13.
Ferris CF. In: Makhlouf GM (Ed.). Handbook of physiology, the gastrointestinal system. vol. II. American Physiological Society, Bethesda (MD), 1989:559-586.
 
14.
Binder EB, Gross R, E, Nemeroff CB, Kilts CD. Eff ects of neurotensin receptor antagonism on latent inhibition in Sprague-Dawley rats. Psychopharmacology 2002;161(3):288-95.
 
15.
Bissette G, Nemeroff BC, Decker MW, Kizer JS, Agid Y, Javoy-Agid F. Alternations in regional brain concentrations of neurotensin and bombesin in Parkinson’s disease. Ann. Neurol1985;17:324-328.
 
16.
O’Connor WT. Functional neuroanatomy of the ventral striopallidal GABA pathway. New sites of intervention in the treatment of schizophrenia. J Neurosci Methods 2001;109(1):31-9.
 
17.
St. Pierre SA, Kerouac R., Quirion R. Neurotensin. In: Hearn MT (Ed.). Peptide and protein reviews, vol.2. Mercel Dekker, New York 1985:83- 171.
 
18.
Carraway RE, Leeman SE. Th e isolation of a new hypotensive peptide, neurotensin from bovine hypothalami. J Biol Chem1973;248:6854- 6861.
 
19.
Kitabgi P. Eff ects of neurotensin on intestinal smooth muscle: Application to the study of structure – activity relationships. Ann NY Acad Sci 1982;400:37-55.
 
20.
Gilbert JA, Richelson E. Neurotensin stimulates formation of cyclic GMP in murine neuroblastoma clone N1E-115. Eur J Pharmacol 1984;99:245-246.
 
21.
Kulińska-Niedziela I, Piątek J, Niedziela M, Paluszak J. Th e eff ect of neurotensin on the lipolytic activity rat adipose tissue and blood under conditions stimulated with glucagon and insulin. J Endocrinol Invest 1996;19(Suppl 3):29.
 
22.
Sankar PM, Carraway RE. Chicken liver contains a large quantity of a G-protein-linked neurotensin receptor. Peptides 1995;16(3):471-477.
 
23.
Azriel Y, Burcher E. Characterization and autoradiographic localization of neurotensin binding sites in human sigmoid colon. J Pharmacol Exp Th er 2001;297(3):1074-81.
 
24.
Martin S, Navarro V, Vincent JP, Mazella J. Neurotensin receptor-1 and -3 complex modulates the cellular signaling of neurotensin in the HT29 cell line. Gastroenterology 2002;123(4):1135-43.
 
25.
Ferris CF, Carraway RE, Hammar RA, Leeman SE. Release and degradation of neurotensin during perfusion of rat small intestine with lipid. Regul Pept 1985;12:101-111.
 
26.
Moody TW, Chiles J, Casibang M, Moody E, Chan D, Davis TP. SR48692 is a neurotensin receptor antagonist which inhibits the growth of small cell lung cancer cells. Peptides 2001;22(1):109-115.
 
27.
Sarret P, Krzywkowski P, Segal L, Nielsen MS, Petersen CM, Mazella J, Stroh T, Beaudet A. Distribution of NTS3 receptor/sortilin mRNA and protein in the rat central nervous system. J Comp Neurol 2003;7, 461(4):483-505.
 
28.
Carraway RE, Bhatnagar YM. Isolation, structure and biological activity of chicken intestinal neurotensin. Peptides 1980;1:167-174.
 
eISSN:1898-2263
ISSN:1232-1966